Association Between MiR-199a Rs74723057 and MET Rs1621 Polymorphisms and the Risk of Hepatocellular Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Nov 5

PMID 27813498

Citations 6

Authors

Qianqian Wang

Xiangyuan Yu

Qiang Li

Linyuan Qin

Shengkui Tan

Xiaoyun Zeng

Xiaoqiang Qiu

Bo Tang

Junfei Jin

Weijia Liao

Moqin Qiu

Lijun Tan

Gaofeng He

Xiaomei Li

Songqing He

Hongping Yu

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) can regulate gene expression at post-transcriptional levels, thereby influence cancer risk. The aim of the current study is to investigate association between miR-199a rs74723057 and MET rs1621 and HCC risk in 1032 HCC patients and 1060 cancer-free controls. These two SNPs were genotyped by using the Agena MassARRAY genotyping system. Odds ratio (OR) and 95% confidence interval (95%CI) were calculated to assess the strength of the associations. We found that compared with the wild-type AA genotype of MET rs1621, the variant GG genotype was associated with a decreased risk for HCC (OR = 0.24, 95% CI = 0.06-0.96, P = 0.043). No association between miR-199a rs74723057 and HCC risk was observed. In addition, an interaction effect on HCC risk between the selected two SNPs was found. Among those who carried the CG/GG genotypes of miR-199a rs74723057, those who carried the GG genotype of MET rs1621 had a reduced risk of HCC, when compared with those who carried the AG/AA genotypes of MET rs1621 (OR = 0.15, 95% CI = 0.03~0.73, P for interaction = 0.018). Our results suggest that MET rs1621 polymorphism, alone and combined with miR-199a rs74723057, may influence susceptibility to HCC. Further large-scale association studies and functional studies are needed to validate our findings.

Citing Articles

The Impact of Variants in Oral Cancer Progression and Clinicopathological Characteristics.

Chen P, Lu Y, Yang W, Su C, Chang L, Yang S J Cancer. 2025; 16(5):1747-1753.

PMID: 39991569 PMC: 11843229. DOI: 10.7150/jca.106426.

MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma?.

Ma R, Zhao M, Zou X, Zhou J, Bai Z Oncol Lett. 2021; 21(4):324.

PMID: 33692856 PMC: 7933756. DOI: 10.3892/ol.2021.12586.

A miR-182 variant and risk of hepatocellular carcinoma in a southern Chinese population.

Qiu M, Liu Y, Lin Q, Zhou Z, Jiang Y, Huo R Hum Genomics. 2020; 14(1):38.

PMID: 33059751 PMC: 7559205. DOI: 10.1186/s40246-020-00289-x.

Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study.

Kalapanida D, Zagouri F, Gazouli M, Tsiakou A, Zografos E, Dimitrakakis C Onco Targets Ther. 2019; 12:4195-4202.

PMID: 31213837 PMC: 6549390. DOI: 10.2147/OTT.S189329.

Single Nucleotide Polymorphisms in Are Associated with the Risk of Hepatocellular Carcinoma in a Southern Chinese Population.

Bei C, Liu S, Yu X, Qiu M, Tang B, Liao W Biomed Res Int. 2019; 2018:1540201.

PMID: 30662901 PMC: 6313975. DOI: 10.1155/2018/1540201.

References

Kim S, Lee U, Kim M, Lee E, Kim J, Lee M . MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem. 2008; 283(26):18158-66. DOI: 10.1074/jbc.M800186200. View

Tsuchiya S, Okuno Y, Tsujimoto G . MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. J Pharmacol Sci. 2006; 101(4):267-70. DOI: 10.1254/jphs.cpj06013x. View

Shen Q, Cicinnati V, Zhang X, Iacob S, Weber F, Sotiropoulos G . Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 2010; 9:227. PMC: 2939569. DOI: 10.1186/1476-4598-9-227. View

Fan Y, Hu D, Feng B, Wang W . The NQO1 C609T polymorphism and hepatocellular carcinoma risk. Tumour Biol. 2014; 35(8):7343-50. DOI: 10.1007/s13277-014-1712-8. View

Ma Y, Wang R, Zhang J, Li W, Gao C, Liu J . Identification of miR-423 and miR-499 polymorphisms on affecting the risk of hepatocellular carcinoma in a large-scale population. Genet Test Mol Biomarkers. 2014; 18(7):516-24. PMC: 4094005. DOI: 10.1089/gtmb.2013.0510. View

Jiang J, Gusev Y, Aderca I, Mettler T, Nagorney D, Brackett D . Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008; 14(2):419-27. PMC: 2755230. DOI: 10.1158/1078-0432.CCR-07-0523. View

Yu M, Yuan J . Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S72-8. DOI: 10.1016/j.gastro.2004.09.018. View

Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, LAbbe D . Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis. 2008; 29(9):1710-6. DOI: 10.1093/carcin/bgn073. View

Lin J, Naujokas M, Zhu H, Nolet S, Park M . Intron-exon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon. Oncogene. 1998; 16(7):833-42. DOI: 10.1038/sj.onc.1201599. View

10.

Iorio M, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P . MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67(18):8699-707. DOI: 10.1158/0008-5472.CAN-07-1936. View

11.

Ryan B, Robles A, Harris C . Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010; 10(6):389-402. PMC: 2950312. DOI: 10.1038/nrc2867. View

12.

Nault J, Zucman-Rossi J . Genetics of hepatobiliary carcinogenesis. Semin Liver Dis. 2011; 31(2):173-87. DOI: 10.1055/s-0031-1276646. View

13.

Nishimura Y, Hyuga S, Takiguchi S, Hyuga M, Itoh K, Hanawa T . Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells. Int J Oncol. 2016; 48(5):1895-906. DOI: 10.3892/ijo.2016.3426. View

14.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

15.

Sattler M, Salgia R . c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 2007; 9(2):102-8. DOI: 10.1007/s11912-007-0005-4. View

16.

Ma P, Maulik G, Christensen J, Salgia R . c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003; 22(4):309-25. DOI: 10.1023/a:1023768811842. View

17.

Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E . Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res. 2007; 35(13):4535-41. PMC: 1935019. DOI: 10.1093/nar/gkm480. View

18.

Lai E . Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002; 30(4):363-4. DOI: 10.1038/ng865. View

19.

Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q . Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011; 19(2):232-43. DOI: 10.1016/j.ccr.2011.01.001. View

20.

Wang R, Ferrell L, Faouzi S, Maher J, Bishop J . Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol. 2001; 153(5):1023-34. PMC: 2174327. DOI: 10.1083/jcb.153.5.1023. View